

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

4 May 2016

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(12 pages by email)

Dear Madam


PRESENTATION AT BIOTECH INVEST 2016

I attach a presentation which is being delivered this week by Biotron Limited to the Biotech Invest conferences in Singapore and Hong Kong. Biotech Invest provides a unique opportunity to showcase the Company's product pipeline and its investment potential to an international audience of investors and potential partners.

As highlighted in the presentation:

- Biotron's lead compound, BIT225, is a first-in-class, novel compound which has been shown to have pan-genotype activity against Hepatitis C (HCV), including hard to treat HCV genotypes 1a, 1b and 3.
- China represents a potentially large market with 30 million people reported to be infected with HCV.
- BIT225 has also shown clinical efficacy in reducing HIV virus levels in hidden reservoirs which are not sensitive to current anti-HIV drugs and which, if untreated, can lead to chronic life-long infection.
- Biotron's core expertise is in the design and development of drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn8471

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

BIOTRON LIMITED

(ASX:BIT)

Singapore Biotech Invest 2016
Asia Biotech Invest 2016

Biotron








Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Biotron Limited Overview

- Clinical stage drug development company
 - Drug development platform for new class of antiviral drugs
 - Phase 2 clinical programs for Hepatitis C virus (HCV) and HIV-1
 - Earlier stage programs include Dengue, Influenza and others
 - Headquartered in Sydney, Australia

INDICATION	COMPOUND	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Hep C	BIT225					
HIV-1/Hep C	BIT225					
HIV-1	BIT225					
Next gen – Hep C	BIT314					
Dengue, Influenza	Leads					

Biotron



Biotron's Core Technology

Designed library of compounds to target **viroporins**:

Initially >250 compounds designed and synthesised; library now ~350

Compounds screened in proprietary assay set up for each virus target e.g. HIV-1 Vpu; HCV p7; Influenza M2; Dengue M; Coronavirus E.

Hits tested against virus in cell cultures

DENGUE – Several compounds with promising antiviral activity

OTHER VIRUSES – Secondary screening of hits against key viruses e.g. Hep B, influenza, Zika, Ebola etc

Lead optimisation and selection

BIT314 (HCV)

BIT225 (HIV-1 and HCV)


OTHER “HITS” IN LIBRARY include:

- Influenza A and B
- Coronaviruses
 - Including SARS
- Epstein-Barr virus (EBV)
- Hepatitis B virus (HBV)

BIT225 is a representation of the value that resides within Biotron's core expertise

Biotron

BIT225 – First of a New Class of HCV DAA Drugs



- ✓ Novel, oral, small molecule compound
- ✓ Only one of its class (p7 inhibitor) in clinical trials
- ✓ Inhibits viral assembly and infectivity
- ✓ Pan-genotype activity:
 - ✓ Active *in vitro* against all main genotypes
 - ✓ Clinically active against hard-to-treat HCV GT 1 (1a and 1b) and GT 3

Positioning BIT225 within HCV Landscape


- HCV market predicted to earn US\$36 billion in 2018
 - 180 million infected worldwide (3% world population)
 - Recent new HCV drug combinations are good, but not optimal
 - Lengthy treatment – 12 weeks or more
 - Not pan-genotypic – **BIT225 is pan-genotypic *in vitro***
 - The new HCV drugs are EXPENSIVE!!!
- Very large markets currently untapped ex-USA/Europe
 - 30 million in China
- Potential for another class of DAA such as BIT225:
 - Shorten treatment times and reduce costs
 - Unmet need in markets within Asia region

HIV-1: Towards a Cure

[WHERE THE VIRUS HIDES]

HIV'S MANY RESERVOIRS

Beyond lying in wait in dormant memory T cells, HIV may reproduce at a low rate in certain other immune system cells—particularly macrophages and dendritic cells that seem inherently able to ward off immune defenses and anti-HIV drugs to some extent. Further, HIV-infected cells in a few parts of the body may be physically shielded to a degree from the immune system and certain drugs. HIV made in cellular and anatomical reservoirs does not reach the blood readily in aggressively treated patients but might generate a vigorous infection if treatment stops.



- HIV-1 remains hidden in reservoirs, leading to chronic, life-long infection
 - Invisible to body's immune defenses
 - Not sensitive to anti-HIV-1 drugs
- Patients need to stay on antiretroviral drugs to keep virus levels under control
- Long-term health implications
- New drugs are needed to eradicate or cure HIV-1 infection
- **BIT225 has shown clinical efficacy in reducing virus levels in reservoir cells**
- **Key Phase 2 trial anticipated to commence mid-2016**



Unlocking Value for Other Virus Targets

- Renewed industry interest in targeting viral diseases including
 - Respiratory syncytial virus (RSV)
 - Hepatitis B virus
 - Tropical diseases including Dengue
 - Influenza (in particular drug resistant strains)
- Ebola and MERS-CoV outbreaks have caused public health issues worldwide
- **BIT225 has demonstrated the robustness of Biotron's approach**
- Compounds with activity against other key viruses; secondary screening is in progress; aim to identifying candidates to progress into IND-enabling studies
- Seeking partnerships for HIV-1 and HCV programs, as well as earlier stage programs, in particular within Asian region



Dengue Virus Program

- 2.5 billion people (40% world population) live in areas at risk of Dengue
- ~100 million people infected yearly
- A leading cause of illness and death in tropics and subtropics
- Transmission is by mosquito; most prevention programs target the vector
- No approved Dengue-specific therapeutic drug
- Vaccine trials have had disappointing results
- Biotron is targeting Dengue M protein – Similar target to HIV-1/Vpu and HCV/p7
 - Several compounds with promising activity have been generated; tests are on-going



Financial Information

Key Financial Metrics

Ticker Code	ASX: BIT
Share Price (29/04/16)	A \$0.063
Market cap	A \$20 million
12 Month Trading Range	A \$0.041 – 0.150
Shares Outstanding	313 million
Options (BITO)	50.7 million \$0.12 expiry 30/09/16

Board


Michael Hoy	Non-executive Chairman
Michelle Miller	Managing Director
Susan Pond	Non-executive Director
Rob Thomas	Non-executive Director
Denis Wade	Non-executive Director

6 Month Share Price Performance

BIT - Daily Line Chart [Close]



BIT - Volume (with MA) [200]



Biotron

Dr Michelle Miller
Managing Director
+61 412 313329
mmiller@biotron.com.au

www.biotron.com.au

Biotron